CD274 and non-small cell lung carcinoma: Results from the Phase III IMpower150 study demonstrated that addition of atezolizumab to bevacizumab plus chemotherapy significantly improved PFS and OS in patients with metastatic nonsquamous NSCLC previously treated with at least one EGFR-TKI, regardless of PD-L1 expression and EGFR or ALK genetic alteration status43.